Latest On Neos Therapeutics, Inc (NEOS):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-03-18 23:23 EST | News | HEXO, CSIQ, LAZR and SIG among premarket gainers | N/A |  |
| 2021-01-06 16:17 EST | Financials | Company financials have been released. | Neutral | |
| 2021-01-01 12:21 EST | Analyst Rating | The Analyst Target Price has decreased from $2 to $1. | Neutral | |
| 2020-12-29 12:12 EST | Analyst Rating | The Analyst Target Price has decreased from $6.5 to $2. | Neutral | |
| 2020-12-14 00:19 EST | Analyst Rating | The Analyst Target Price has increased from $4.67 to $6.5. | Buy | |
| 2020-12-11 12:15 EST | Analyst Rating | The Analyst Target Price has decreased from $5.5 to $4.67. | Neutral | |
| 2020-12-10 15:44 EST | News | Aytu BioScience buying Neos Therapeutics for $44.9M in stock | N/A | |
| 2020-11-26 20:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 12:23 EST | Analyst Rating | The Analyst Target Price has decreased from $5.75 to $5.5. | Neutral | |
| 2020-11-12 04:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-11 04:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-10 12:39 EST | Analyst Rating | The Analyst Target Price has decreased from $6.75 to $5.75. | Neutral | |
| 2020-11-09 14:56 EST | News | Neos Therapeutics EPS misses by $0.05, misses on revenue | N/A | |
| 2020-11-09 14:53 EST | News | Neos Therapeutics' (NEOS) CEO Jerry McLaughlin on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-07 16:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 13:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 05:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-15 01:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 09:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-12 05:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-11 21:27 EST | Analyst Rating | The Analyst Target Price has decreased from $7 to $6.75. | Neutral | |
| 2020-08-10 18:15 EST | News | Neos Therapeutics EPS beats by $0.02, beats on revenue | N/A | |
| 2020-08-10 18:14 EST | News | Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q2 2020 Results - Earnings Call Transcript | N/A | |
| 2020-08-06 13:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 01:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 05:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 13:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 17:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-15 19:34 EST | News | Neos Therapeutics Is Hitting A Considerable Air Pocket | N/A | |
| 2020-07-09 09:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 17:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-26 09:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 05:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 05:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-11 21:11 EST | Insider Trade | Bryant Fong has directly acquired 23,453 shares and currently holds 24,953 shares. | Buy | |
| 2020-06-11 21:11 EST | Insider Trade | Beth Hecht has directly acquired 23,453 shares and currently holds 23,453 shares. | Buy | |
| 2020-06-11 21:11 EST | Insider Trade | ALAN L HELLER has directly acquired 23,453 shares and currently holds 446,819 shares. | Buy | |
| 2020-06-11 21:11 EST | Insider Trade | James A. Jr. Robinson has directly acquired 23,453 shares and currently holds 23,453 shares. | Buy | |
| 2020-06-11 21:10 EST | Insider Trade | GREGORY J ROBITAILLE has directly acquired 23,453 shares and currently holds 79,130 shares. | Buy | |
| 2020-06-11 21:10 EST | Insider Trade | John P. Schmid has directly acquired 23,453 shares and currently holds 23,453 shares. | Buy | |
| 2020-06-11 21:10 EST | Insider Trade | Linda M Szyper has directly acquired 23,453 shares and currently holds 23,453 shares. | Buy | |
| 2020-06-02 09:14 EST | Earnings Estimate | An EPS average of -$0.04 is estimated for the quarter ending on September 30, 2020. | Buy | |
| 2020-05-27 05:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-15 20:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-11 23:35 EST | News | Neos Therapeutics EPS misses by $0.07, misses on revenue | N/A | |
| 2020-05-11 23:35 EST | News | Neos Therapeutics. Inc. (NEOS) CEO Jerry McLaughlin on Q1 2020 Results - Earnings Call Transcript | N/A | |
| 2020-05-06 05:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 05:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-29 06:26 EST | News | Neos Therapeutics: Failure To Re-Launch | N/A | |
| 2020-04-12 04:12 EST | News | Neos Therapeutics EPS misses by $0.04, misses on revenue | N/A | |
About Neos Therapeutics, Inc (NEOS):
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.
General
- Name Neos Therapeutics, Inc
- Symbol NEOS
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 213
- Fiscal Year EndDecember
- IPO Date2015-07-23
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.neostx.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 0.8
- Enterprise Value Revenue 1.35
View More
Financials
- Most Recent Quarter 2020-09-30
- Profit Margin -38%
- Operating Margin -24%
- Return on Assets -11%
- Revenue 56.99 million
- Earnings Per Share -$0.78
- Revenue Per Share $1.15
- Gross Profit 39.53 million
- Quarterly Earnings Growth -28.5%
View More
Highlights
- Market Capitalization 65.19 million
- EBITDA -22108000
- PEG Ratio -0.02
- Analyst Target Price $1
- Book Value Per Share -$0.03
View More
Share Statistics
- Shares Outstanding 49.76 million
- Shares Float 44.26 million
- % Held by Insiders 150%
- % Held by Institutions 33.38%
- Shares Short 1.17 million
- Shares Short Prior Month 1.29 million
- Short Ratio 0.24
- Short % of Float 2%
- Short % of Shares Outstanding 2%
View More
Technicals
- Beta 1.45
- 52 Week High $1.68
- 52 Week Low $0.45
- 50 Day Moving Average 0.94
- 200 Day Moving Average 0.72
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Neos Therapeutics, Inc (NEOS) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Neos Therapeutics, Inc (NEOS) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-09 | $12.54 million | -$0.10 | -$0.05 | -87.62% |
| 2020-06-30 | 2020-08-10 | $N/A | -$0.11 | -$0.13 | 15.38% |
| 2020-03-31 | 2020-05-11 | $14.49 million | -$0.16 | -$0.09 | -72.97% |
| 2019-12-31 | 2020-03-13 | $16.83 million | -$0.07 | -$0.03 | -115.38% |
| 2019-09-30 | 2019-11-08 | $17.54 million | -$0.04 | -$0.11 | 64.44% |
| 2019-06-30 | 2019-08-08 | $15.64 million | -$0.08 | -$0.17 | 52.38% |
| 2019-03-31 | 2019-05-09 | $14.63 million | -$0.15 | -$0.20 | 25% |
| 2018-12-31 | 2019-03-14 | $15.39 million | -$0.23 | -$0.28 | 17.27% |
| 2018-09-30 | 2018-11-09 | $12.5 million | -$0.43 | -$0.41 | -3.86% |
| 2018-06-30 | 2018-08-08 | $11.36 million | -$0.52 | -$0.44 | -18.18% |
| 2018-03-31 | 2018-05-09 | $10.73 million | -$0.50 | -$0.49 | -1.52% |
| 2017-12-31 | 2018-03-15 | $7.79 million | -$0.49 | -$0.61 | 19.49% |
| 2017-09-30 | 2017-11-08 | $7.1 million | -$0.58 | -$0.75 | 22.47% |
| 2017-06-30 | 2017-08-08 | $5.18 million | -$0.83 | -$0.83 | 0.29% |
| 2017-03-31 | 2017-05-09 | $5.63 million | -$0.87 | -$0.92 | 5.72% |
| 2016-12-31 | 2017-03-14 | $3.5 million | -$1.14 | -$1.36 | 16.29% |
| 2016-09-30 | 2016-11-10 | $1.58 million | -$1.61 | -$1.64 | 1.6% |
| 2016-06-30 | 2016-08-11 | $1.49 million | -$1.65 | -$1.37 | -20.81% |
| 2016-03-31 | 2016-05-16 | $2.58 million | -$0.79 | -$0.83 | 5.04% |
| 2015-12-31 | 2016-03-17 | $1.66 million | -$0.57 | -$0.71 | 19.75% |
| 2015-09-30 | 2015-11-13 | $221000 | -$0.77 | -$0.57 | -35.09% |
| 2015-06-30 | 2015-07-28 | $1.48 million | -$7.76 | -$4.53 | -71.3% |
Neos Therapeutics, Inc (NEOS) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | 1.31 million | N/A | 2.04 million | 1.83 million | 1.55 million |
| Income Before Tax | -4.91 million | N/A | -7.95 million | -3.48 million | -2.05 million |
| Selling General Administrative | 9.02 million | N/A | 11.96 million | 9.54 million | 9.98 million |
| Gross Profit | 7.42 million | N/A | 8.1 million | 9.65 million | 11.09 million |
| Ebit | -2.9 million | N/A | -4.99 million | -1.72 million | -433000 |
| Operating Income | -2.92 million | N/A | -5.89 million | -1.72 million | -433000 |
| Income Tax Expense | N/A | N/A | N/A | 11000 | N/A |
| Total Revenue | 12.54 million | N/A | 14.49 million | 16.83 million | 17.54 million |
| Cost of Revenue | 5.12 million | N/A | 6.39 million | 7.18 million | 6.45 million |
| Total Other Income Expense Net | 12000 | N/A | -25000 | -1.76 million | -1.62 million |
| Net Income From Continuing Operations | -4.91 million | N/A | -7.95 million | -3.49 million | -2.05 million |
| Net Income Applicable to Common Shares | N/A | -5.51 million | N/A | -3.49 million | -2.05 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | 3.89 million | 3.91 million | N/A | N/A |
| Change to Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | -14.54 million | 8.12 million | N/A | N/A |
| Change to Operating Activities | N/A | N/A | N/A | N/A | N/A |
| Change in Cash | N/A | -15.18 million | 11.03 million | N/A | N/A |
| Total Cash from Operating Activities | N/A | -4.53 million | -999000 | N/A | N/A |
| Depreciation | N/A | 914000 | 925000 | N/A | N/A |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | 1.49 million | 792000 | N/A | N/A |
| Change to Account Receivables | N/A | 3.4 million | 5.78 million | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | N/A | N/A | N/A | N/A | N/A |
| Capital Expenditures | N/A | 106000 | 190000 | N/A | N/A |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 85.14 million | N/A | 102.27 million | 97 million | 94.78 million |
| Total Stockholder Equity | -20.55 million | N/A | -13.18 million | -6.13 million | -3.03 million |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Assets | 64.58 million | N/A | 89.09 million | 90.87 million | 91.76 million |
| Common Stock | 50000 | 50000 | N/A | 50000 | 50000 |
| Other Current Assets | N/A | N/A | N/A | N/A | 1.76 million |
| Retained Earnings | -352.25 million | -347.34 million | -341.84 million | -333.89 million | -330.4 million |
| Other Liabilities | 1.51 million | 1.94 million | N/A | 1.3 million | 1.42 million |
| Other Assets | 1.02 million | 1.15 million | N/A | 1.38 million | 304000 |
| Cash | 12.74 million | N/A | 27.86 million | 16.83 million | 23.28 million |
| Total Current Liabilities | 67.16 million | N/A | 68.4 million | 63.36 million | 61.14 million |
| Other Stockholder Equity | N/A | N/A | N/A | 1000 | N/A |
| Property, Plant & Equipment | 8.48 million | 9.43 million | N/A | 10.39 million | 10.68 million |
| Total Current Assets | 44.01 million | N/A | 65.75 million | 66.56 million | 67.59 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | -31.63 million | -27.88 million | N/A | -18.67 million | -16.22 million |
| Short Term Investments | N/A | N/A | 3.99 million | 8.06 million | 1.99 million |
| Long Term Debt | 13.72 million | N/A | 29.42 million | 29.1 million | 28.79 million |
| Inventory | 8.44 million | N/A | 10.22 million | 11.01 million | 11.68 million |
| Accounts Payable | 8.44 million | N/A | 13.03 million | 6.65 million | 6.55 million |
Neos Therapeutics, Inc (NEOS) Chart:
Neos Therapeutics, Inc (NEOS) News:
Below you will find a list of latest news for Neos Therapeutics, Inc (NEOS) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Neos Therapeutics, Inc (NEOS) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Neos Therapeutics, Inc (NEOS) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000155837020007668/0001558370-20-007668-index.htm |
| 2018-12-17 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1467652/000000000018038312/0000000000-18-038312-index.htm |
| 2019-03-21 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1467652/000000000019005435/0000000000-19-005435-index.htm |
| 2019-01-28 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1467652/000003877719000051/0000038777-19-000051-index.htm |
| 2018-12-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1467652/000021545718007272/0000215457-18-007272-index.htm |
| 2019-02-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1467652/000021545719006788/0000215457-19-006788-index.htm |
| 2019-07-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1467652/000021545719008350/0000215457-19-008350-index.htm |
| 2020-01-31 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1467652/000076999320000083/0000769993-20-000083-index.htm |
| 2019-01-03 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1467652/000091957419000044/0000919574-19-000044-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1467652/000091957420001155/0000919574-20-001155-index.htm |
| 2018-11-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1467652/000093583618000600/0000935836-18-000600-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1467652/000093583619000095/0000935836-19-000095-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1467652/000093583620000115/0000935836-20-000115-index.htm |
| 2018-11-05 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1467652/000104746918007052/0001047469-18-007052-index.htm |
| 2018-11-05 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1467652/000104746918007053/0001047469-18-007053-index.htm |
| 2018-11-06 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1467652/000104746918007085/0001047469-18-007085-index.htm |
| 2018-12-11 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1467652/000104746918007597/0001047469-18-007597-index.htm |
| 2018-12-20 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1467652/000104746918007758/0001047469-18-007758-index.htm |
| 2019-03-18 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1467652/000104746919001344/0001047469-19-001344-index.htm |
| 2019-03-18 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1467652/000104746919001351/0001047469-19-001351-index.htm |
| 2019-04-24 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1467652/000104746919002545/0001047469-19-002545-index.htm |
| 2020-04-21 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1467652/000104746920002475/0001047469-20-002475-index.htm |
| 2018-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1467652/000110465918031930/0001104659-18-031930-index.htm |
| 2018-06-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000110465918041805/0001104659-18-041805-index.htm |
| 2018-06-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000110465918042601/0001104659-18-042601-index.htm |
| 2018-06-28 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465918042931/0001104659-18-042931-index.htm |
| 2018-06-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465918042932/0001104659-18-042932-index.htm |
| 2018-07-02 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1467652/000110465918043554/0001104659-18-043554-index.htm |
| 2018-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465918043858/0001104659-18-043858-index.htm |
| 2018-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465918043859/0001104659-18-043859-index.htm |
| 2018-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465918043860/0001104659-18-043860-index.htm |
| 2018-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465918043861/0001104659-18-043861-index.htm |
| 2018-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465918043862/0001104659-18-043862-index.htm |
| 2018-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465918043863/0001104659-18-043863-index.htm |
| 2018-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000110465918050322/0001104659-18-050322-index.htm |
| 2018-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1467652/000110465918050753/0001104659-18-050753-index.htm |
| 2018-10-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000110465918063669/0001104659-18-063669-index.htm |
| 2018-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000110465918066013/0001104659-18-066013-index.htm |
| 2018-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000110465918066376/0001104659-18-066376-index.htm |
| 2018-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000110465918066858/0001104659-18-066858-index.htm |
| 2018-11-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465918066979/0001104659-18-066979-index.htm |
| 2018-11-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000110465918067139/0001104659-18-067139-index.htm |
| 2018-11-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1467652/000110465918067395/0001104659-18-067395-index.htm |
| 2018-11-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000110465918070734/0001104659-18-070734-index.htm |
| 2018-12-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465918071882/0001104659-18-071882-index.htm |
| 2018-12-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465918072099/0001104659-18-072099-index.htm |
| 2018-12-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000110465918072389/0001104659-18-072389-index.htm |
| 2018-12-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465918072812/0001104659-18-072812-index.htm |
| 2018-12-18 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1467652/000110465918073569/0001104659-18-073569-index.htm |
| 2018-12-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000110465918074634/0001104659-18-074634-index.htm |
| 2019-01-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000110465919004302/0001104659-19-004302-index.htm |
| 2019-01-30 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465919004505/0001104659-19-004505-index.htm |
| 2019-01-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465919004506/0001104659-19-004506-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465919012421/0001104659-19-012421-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465919012433/0001104659-19-012433-index.htm |
| 2019-03-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000110465919014712/0001104659-19-014712-index.htm |
| 2019-03-18 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1467652/000110465919015421/0001104659-19-015421-index.htm |
| 2019-03-22 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465919016881/0001104659-19-016881-index.htm |
| 2019-03-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465919016882/0001104659-19-016882-index.htm |
| 2019-03-22 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465919016914/0001104659-19-016914-index.htm |
| 2019-04-24 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1467652/000110465919023426/0001104659-19-023426-index.htm |
| 2019-04-29 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1467652/000110465919024521/0001104659-19-024521-index.htm |
| 2019-05-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000110465919028001/0001104659-19-028001-index.htm |
| 2019-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1467652/000110465919028440/0001104659-19-028440-index.htm |
| 2019-06-17 | 3/A | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465919035979/0001104659-19-035979-index.htm |
| 2019-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465919035980/0001104659-19-035980-index.htm |
| 2019-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465919035981/0001104659-19-035981-index.htm |
| 2019-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465919035982/0001104659-19-035982-index.htm |
| 2019-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465919035983/0001104659-19-035983-index.htm |
| 2019-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465919035984/0001104659-19-035984-index.htm |
| 2019-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465919035985/0001104659-19-035985-index.htm |
| 2019-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465919035986/0001104659-19-035986-index.htm |
| 2019-06-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000110465919036179/0001104659-19-036179-index.htm |
| 2019-10-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000110465919052850/0001104659-19-052850-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1467652/000110465920020220/0001104659-20-020220-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465920029264/0001104659-20-029264-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465920029267/0001104659-20-029267-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465920029269/0001104659-20-029269-index.htm |
| 2020-03-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465920034240/0001104659-20-034240-index.htm |
| 2020-04-21 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1467652/000110465920049205/0001104659-20-049205-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465920072544/0001104659-20-072544-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465920072546/0001104659-20-072546-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465920072548/0001104659-20-072548-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465920072549/0001104659-20-072549-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465920072550/0001104659-20-072550-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465920072551/0001104659-20-072551-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1467652/000110465920072552/0001104659-20-072552-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1467652/000114420419007732/0001144204-19-007732-index.htm |
| 2019-07-02 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1467652/000117891319001797/0001178913-19-001797-index.htm |
| 2020-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1467652/000117891320000339/0001178913-20-000339-index.htm |
| 2018-11-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1467652/000119380518001313/0001193805-18-001313-index.htm |
| 2018-11-30 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1467652/000119380518001380/0001193805-18-001380-index.htm |
| 2019-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000155837019007584/0001558370-19-007584-index.htm |
| 2019-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1467652/000155837019007801/0001558370-19-007801-index.htm |
| 2019-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000155837019010498/0001558370-19-010498-index.htm |
| 2019-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1467652/000155837019010615/0001558370-19-010615-index.htm |
| 2020-03-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000155837020002616/0001558370-20-002616-index.htm |
| 2020-03-13 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1467652/000155837020002684/0001558370-20-002684-index.htm |
| 2020-03-13 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1467652/000155837020002685/0001558370-20-002685-index.htm |
| 2020-03-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000155837020003315/0001558370-20-003315-index.htm |
| 2020-04-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000155837020003737/0001558370-20-003737-index.htm |
| 2020-04-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000155837020004217/0001558370-20-004217-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000155837020005576/0001558370-20-005576-index.htm |
| 2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000155837020006257/0001558370-20-006257-index.htm |
| 2020-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1467652/000155837020006303/0001558370-20-006303-index.htm |
| 2020-06-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000155837020007211/0001558370-20-007211-index.htm |
| 2020-06-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000155837020007454/0001558370-20-007454-index.htm |
| 2020-06-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000155837020007668/0001558370-20-007668-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1467652/000155837020010035/0001558370-20-010035-index.htm |
| 2020-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1467652/000155837020010196/0001558370-20-010196-index.htm |
| 2018-12-20 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1467652/999999999518003187/9999999995-18-003187-index.htm |
| 2019-05-01 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1467652/999999999519000975/9999999995-19-000975-index.htm |
| 2019-04-01 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1467652/999999999719002229/9999999997-19-002229-index.htm |
Neos Therapeutics, Inc (NEOS) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Neos Therapeutics, Inc (NEOS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 150%Institutional Ownership: 3338%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-03-02 | Richard I Eisenstadt | Chief Financial Officer | Buy | 100,000.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1467652/000110465920029264/0001104659-20-029264-index.htm | ||
| 2020-03-02 | John M Limongelli | SVP & General Counsel | Buy | 100,000.00 | 100,000.00 | https://www.sec.gov/Archives/edgar/data/1467652/000110465920029269/0001104659-20-029269-index.htm | ||
| 2020-06-10 | Beth Hecht | Director | Buy | 23,453.00 | 23,453.00 | https://www.sec.gov/Archives/edgar/data/1467652/000110465920072546/0001104659-20-072546-index.htm | ||
| 2020-06-10 | James A. Jr. Robinson | Director | Buy | 23,453.00 | 23,453.00 | https://www.sec.gov/Archives/edgar/data/1467652/000110465920072549/0001104659-20-072549-index.htm | ||
| 2020-06-10 | John P. Schmid | Director | Buy | 23,453.00 | 23,453.00 | https://www.sec.gov/Archives/edgar/data/1467652/000110465920072551/0001104659-20-072551-index.htm | ||
| 2020-06-10 | Linda M Szyper | Director | Buy | 23,453.00 | 23,453.00 | https://www.sec.gov/Archives/edgar/data/1467652/000110465920072552/0001104659-20-072552-index.htm | ||
| 2018-12-06 | Gerald W. McLaughlin | Chief Executive Officer | Buy | 17,097.00 | 2.11 | 36,119.12 | 24,500.00 | https://www.sec.gov/Archives/edgar/data/1467652/000110465918072099/0001104659-18-072099-index.htm |
| 2020-06-10 | Bryant Fong | Director | Buy | 23,453.00 | 24,953.00 | https://www.sec.gov/Archives/edgar/data/1467652/000110465920072544/0001104659-20-072544-index.htm | ||
| 2020-03-02 | Gerald W. McLaughlin | Chief Executive Officer | Buy | 290,000.00 | 314,500.00 | https://www.sec.gov/Archives/edgar/data/1467652/000110465920029267/0001104659-20-029267-index.htm | ||
| 2018-11-08 | ALAN L HELLER | Director | Buy | 43,478.00 | 2.30 | 99,999.40 | 423,366.00 | https://www.sec.gov/Archives/edgar/data/1467652/000110465918066979/0001104659-18-066979-index.htm |
| 2018-12-12 | Richard I Eisenstadt | Chief Financial Officer | Buy | 5,000.00 | 2.16 | 10,819.50 | 42,460.00 | https://www.sec.gov/Archives/edgar/data/1467652/000110465918072812/0001104659-18-072812-index.htm |
| 2020-06-10 | ALAN L HELLER | Director | Buy | 23,453.00 | 446,819.00 | https://www.sec.gov/Archives/edgar/data/1467652/000110465920072548/0001104659-20-072548-index.htm | ||
| 2018-12-04 | Gerald W. McLaughlin | Chief Executive Officer | Buy | 7,403.00 | 2.04 | 15,119.89 | 7,403.00 | https://www.sec.gov/Archives/edgar/data/1467652/000110465918071882/0001104659-18-071882-index.htm |
| 2020-06-10 | GREGORY J ROBITAILLE | Director | Buy | 23,453.00 | 79,130.00 | https://www.sec.gov/Archives/edgar/data/1467652/000110465920072550/0001104659-20-072550-index.htm |